| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
91,540,000 |
| Market
Cap: |
34.79(M) |
| Last
Volume: |
1,296,467 |
Avg
Vol: |
1,292,882 |
| 52
Week Range: |
$0.38 - $0.9341 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tobin James R |
Director |
– • – |
2011-03-30 |
4 |
S |
$3.27 |
$39,197 |
D/D |
(11,987) |
46,751 |
|
- |
|
| Tobin James R |
Director |
– • – |
2011-03-30 |
4 |
OE |
$3.13 |
$39,125 |
D/D |
12,500 |
58,738 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2011-03-30 |
4 |
S |
$3.28 |
$82,000 |
D/D |
(25,000) |
1,147,188 |
|
- |
|
| Passeri Daniel R |
CEO and Director |
• – – |
2011-03-30 |
4 |
S |
$3.27 |
$87,963 |
D/D |
(26,900) |
65,000 |
|
- |
|
| Passeri Daniel R |
CEO and Director |
• – – |
2011-03-30 |
4 |
OE |
$3.13 |
$84,197 |
D/D |
26,900 |
91,900 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2011-03-29 |
4 |
S |
$3.28 |
$82,000 |
D/D |
(25,000) |
1,172,188 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2011-03-18 |
4 |
OE |
$1.07 |
$556,600 |
D/D |
397,500 |
1,197,188 |
|
- |
|
| Rubin Marc |
Director |
– • – |
2010-12-10 |
4 |
B |
$1.89 |
$50,266 |
D/D |
26,596 |
26,596 |
2.39 |
- |
|
| Tobin James R |
Director |
– • – |
2010-10-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(46,238) |
46,239 |
|
- |
|
| Passeri Daniel R |
CEO |
• • – |
2010-08-31 |
5 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
65,000 |
|
- |
|
| Bvf Inc/il |
Indirect Beneficial Owner |
– – • |
2009-04-27 |
4 |
S |
$1.15 |
$3,415,500 |
I/I |
(2,970,000) |
5,951,716 |
|
- |
|
| Bvf Inc/il |
10% Owner |
– – • |
2009-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,921,716 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2008-12-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,000 |
799,688 |
|
- |
|
| Gray Michael |
COO and CFO |
• – – |
2008-10-24 |
4 |
A |
$0.01 |
$791 |
D/D |
79,113 |
86,613 |
|
- |
|
| Passeri Daniel R |
CEO |
• • – |
2008-10-01 |
4 |
OE |
$1.09 |
$21,800 |
D/D |
20,000 |
75,000 |
|
- |
|
| Gray Michael |
COO and CFO |
• – – |
2008-10-01 |
4 |
OE |
$1.09 |
$8,175 |
D/D |
7,500 |
7,500 |
|
- |
|
| Passeri Daniel R |
CEO and Director |
• • – |
2008-08-07 |
4 |
B |
$1.55 |
$31,000 |
D/D |
20,000 |
55,000 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2008-08-06 |
4/A |
B |
$1.56 |
$78,185 |
I/I |
50,000 |
150,000 |
2.1 |
- |
|
| Mcnab James R |
Director |
– • – |
2008-08-06 |
4 |
S |
$1.56 |
$78,185 |
I/I |
(50,000) |
150,000 |
|
- |
|
| Noel Mark |
Vice-President |
• – – |
2008-06-13 |
5 |
A |
$0.88 |
$3,150 |
D/D |
3,579 |
27,540 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2008-06-06 |
4 |
S |
$1.36 |
$71,228 |
D/D |
(50,000) |
874,688 |
|
- |
|
| Kolchinsky Peter |
10% Owner |
– – • |
2008-04-15 |
4 |
S |
$1.40 |
$1,820,000 |
I/I |
(1,300,000) |
6,250,564 |
|
- |
|
| Noel Mark |
VP, Tech Management |
• – – |
2007-12-14 |
5 |
A |
$0.97 |
$3,153 |
D/D |
3,251 |
23,961 |
|
- |
|
| Ra Capital Biotech Fund Ii, L.p. |
10% Owner |
– – • |
2007-08-08 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
7,550,564 |
|
- |
|
| Ra Capital Biotech Fund Lp |
10% Owner |
– – • |
2007-08-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,520,564 |
|
- |
|
303 Records found
|
|
Page 6 of 13 |
|
|
